PURPOSE: To evaluate the effect of oral @entity617 on visual outcomes and complications of scleral buckling (SB) in phakic eyes with @entity1713 ( @entity1713 ). METHODS: In a randomized double-blind placebo-controlled trial, @entity1 with acute @entity1713 underwent SB. The treatment group received 1 mg/kg oral @entity617 for 10 days while the control group received placebo. Outcome measures included visual acuity (VA), retinal redetachment (re-RD), @entity1103 ( @entity1103 ), proliferative @entity1715 (PVR), and other possible @entity260 . Outcome measures were compared between groups with McNemar test. RESULTS: Overall, 52 eyes of 52 subjects were enrolled into the study, which included 25 and 27 eyes in the treatment and placebo groups, respectively. Preoperatively, the extent and location of RD and rate of @entity8814 was comparable between the study groups. VA improvement (logMAR) was 0.75+/-0.61 overall: 0.85+/-0.62 in the treatment group versus 0.65+/-0.61 in the placebo group (p=0.36). @entity260 in the treatment and placebo groups included @entity1713 , 3 versus 4 eyes (p=0.45), significant PVR, 1 versus 3 (p=0.33), and @entity1103 , 3 versus 5 eyes (p=0.39), respectively. CONCLUSIONS: Postoperative oral @entity617 does not seem to improve the visual outcomes and complications of scleral buckling in simple phakic @entity1713 .

Effect of oral XXXX on visual outcomes and complications after scleral buckling.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1715 :: ('MESH:D018630', 'Disease') :: ['vitreoretinopathy'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['choroidal detachment', 'RRD', 'acute rhegmatogenous retinal detachment'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['CME', 'cystoid macular edema'] @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications', 'Postoperative complications'] @entity8814 :: ('MESH:D015814', 'Disease') :: ['hypotony'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']
@entity617 :: (MESH:D011239,Chemical) :: ['prednisolone']
